170 related articles for article (PubMed ID: 15004150)
1. Improved immunogenicity of an immunodominant epitope of the HER-2/neu protooncogene by alterations of MHC contact residues.
Vertuani S; Sette A; Sidney J; Southwood S; Fikes J; Keogh E; Lindencrona JA; Ishioka G; Levitskaya J; Kiessling R
J Immunol; 2004 Mar; 172(6):3501-8. PubMed ID: 15004150
[TBL] [Abstract][Full Text] [Related]
2. Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity.
Keogh E; Fikes J; Southwood S; Celis E; Chesnut R; Sette A
J Immunol; 2001 Jul; 167(2):787-96. PubMed ID: 11441084
[TBL] [Abstract][Full Text] [Related]
3. Identification of major epitopes of Mycobacterium tuberculosis AG85B that are recognized by HLA-A*0201-restricted CD8+ T cells in HLA-transgenic mice and humans.
Geluk A; van Meijgaarden KE; Franken KL; Drijfhout JW; D'Souza S; Necker A; Huygen K; Ottenhoff TH
J Immunol; 2000 Dec; 165(11):6463-71. PubMed ID: 11086086
[TBL] [Abstract][Full Text] [Related]
4. HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice.
Vertuani S; Triulzi C; Roos AK; Charo J; Norell H; Lemonnier F; Pisa P; Seliger B; Kiessling R
Cancer Immunol Immunother; 2009 May; 58(5):653-64. PubMed ID: 18820911
[TBL] [Abstract][Full Text] [Related]
5. Epitope-enhanced conserved HIV-1 peptide protects HLA-A2-transgenic mice against virus expressing HIV-1 antigen.
Okazaki T; Pendleton CD; Lemonnier F; Berzofsky JA
J Immunol; 2003 Sep; 171(5):2548-55. PubMed ID: 12928405
[TBL] [Abstract][Full Text] [Related]
6. Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants.
Hoffmann TK; Nakano K; Elder EM; Dworacki G; Finkelstein SD; Appella E; Whiteside TL; DeLeo AB
J Immunol; 2000 Nov; 165(10):5938-44. PubMed ID: 11067956
[TBL] [Abstract][Full Text] [Related]
7. Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice.
Ercolini AM; Machiels JP; Chen YC; Slansky JE; Giedlen M; Reilly RT; Jaffee EM
J Immunol; 2003 Apr; 170(8):4273-80. PubMed ID: 12682262
[TBL] [Abstract][Full Text] [Related]
8. Changes in an HER-2 peptide upregulating HLA-A2 expression affect both conformational epitopes and CTL recognition: implications for optimization of antigen presentation and tumor-specific CTL induction.
Fisk B; Savary C; Hudson JM; O'Brian CA; Murray JL; Wharton JT; Ioannides CG
J Immunother Emphasis Tumor Immunol; 1995 Nov; 18(4):197-209. PubMed ID: 8680648
[TBL] [Abstract][Full Text] [Related]
9. Inefficient cross-presentation limits the CD8+ T cell response to a subdominant tumor antigen epitope.
Otahal P; Hutchinson SC; Mylin LM; Tevethia MJ; Tevethia SS; Schell TD
J Immunol; 2005 Jul; 175(2):700-12. PubMed ID: 16002665
[TBL] [Abstract][Full Text] [Related]
10. Accelerated HER-2 degradation enhances ovarian tumor recognition by CTL. Implications for tumor immunogenicity.
Castilleja A; Ward NE; O'Brian CA; Swearingen B; Swan E; Gillogly MA; Murray JL; Kudelka AP; Gershenson DM; Ioannides CG
Mol Cell Biochem; 2001 Jan; 217(1-2):21-33. PubMed ID: 11269662
[TBL] [Abstract][Full Text] [Related]
11. HLA anchor optimization of the melan-A-HLA-A2 epitope within a long peptide is required for efficient cross-priming of human tumor-reactive T cells.
Chauvin JM; Larrieu P; Sarrabayrouse G; Prévost-Blondel A; Lengagne R; Desfrançois J; Labarrière N; Jotereau F
J Immunol; 2012 Mar; 188(5):2102-10. PubMed ID: 22291187
[TBL] [Abstract][Full Text] [Related]
12. The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53(264-272) epitope.
Hoffmann TK; Loftus DJ; Nakano K; Maeurer MJ; Chikamatsu K; Appella E; Whiteside TL; DeLeo AB
J Immunol; 2002 Feb; 168(3):1338-47. PubMed ID: 11801674
[TBL] [Abstract][Full Text] [Related]
13. CTLs directed against HER2 specifically cross-react with HER3 and HER4.
Conrad H; Gebhard K; Krönig H; Neudorfer J; Busch DH; Peschel C; Bernhard H
J Immunol; 2008 Jun; 180(12):8135-45. PubMed ID: 18523278
[TBL] [Abstract][Full Text] [Related]
14. Enzymatic discovery of a HER-2/neu epitope that generates cross-reactive T cells.
Henle AM; Erskine CL; Benson LM; Clynes R; Knutson KL
J Immunol; 2013 Jan; 190(1):479-88. PubMed ID: 23180824
[TBL] [Abstract][Full Text] [Related]
15. Generation of human tumor-specific CTLs in HLA-A2.1-transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumors.
Gritzapis AD; Sotiriadou NN; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2004 Nov; 53(11):1027-40. PubMed ID: 15164233
[TBL] [Abstract][Full Text] [Related]
16. Derivation of HLA-B*0702 transgenic mice: functional CTL repertoire and recognition of human B*0702-restricted CTL epitopes.
Alexander J; Oseroff C; Sidney J; Sette A
Hum Immunol; 2003 Feb; 64(2):211-23. PubMed ID: 12559623
[TBL] [Abstract][Full Text] [Related]
17. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
Zaremba S; Barzaga E; Zhu M; Soares N; Tsang KY; Schlom J
Cancer Res; 1997 Oct; 57(20):4570-7. PubMed ID: 9377571
[TBL] [Abstract][Full Text] [Related]
18. Induction of tumor-reactive CTL by C-side chain variants of the CTL epitope HER-2/neu protooncogene (369-377) selected by molecular modeling of the peptide: HLA-A2 complex.
Castilleja A; Carter D; Efferson CL; Ward NE; Kawano K; Fisk B; Kudelka AP; Gershenson DM; Murray JL; O'Brian CA; Ioannides CG
J Immunol; 2002 Oct; 169(7):3545-54. PubMed ID: 12244144
[TBL] [Abstract][Full Text] [Related]
19. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
[TBL] [Abstract][Full Text] [Related]
20. The immunodominant, Ld-restricted T cell response to hepatitis B surface antigen (HBsAg) efficiently suppresses T cell priming to multiple Dd-, Kd-, and Kb-restricted HBsAg epitopes.
Schirmbeck R; Stober D; El-Kholy S; Riedl P; Reimann J
J Immunol; 2002 Jun; 168(12):6253-62. PubMed ID: 12055239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
